secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0001437749-24-018934
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics adopts Executive Severance Plan for named executive officers
--------------------------------------------------------------------------------

- CEO Carmine Stengone designated Tier 1 participant; CSO Lorrain, CFO Slover designated Tier 2 participants.
- Non-CIC severance: 12 months base salary + pro-rata bonus; health coverage up to 12 months.
- CIC severance: 150% (Tier1) or 100% (Tier2) of salary+bonus; equity acceleration; health to 18/12 mo.
- Plan replaces prior severance agreements; participants must sign release and arbitration agreement.
- Plan effective May 24; participation agreements executed May 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924018934/0001437749-24-018934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774924018934/cont20240524_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-018934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer